Naibec to Participate in 2024 AACR... 'Unveiling Next-Generation Anticancer Drug Platform'

Naivek, a peptide fusion bio-specialized company, announced on the 13th that it will participate in the world's largest 'American Association for Cancer Research (AACR)' and present research results on its self-developed mutant K-RAS targeted degradation anticancer drug.

Naivek's new anticancer agent is a next-generation protein degradation anticancer drug composed of a pan K-RAS binding function 'antibody fragment (scFv)' with cancer cell-specific permeability and a proteasome (a protein complex that degrades proteins) inducing sequence. This anticancer drug shows excellent effects on various tumor cells mediated by mutant resistant K-RAS. Since it is designed with a target cell-permeable peptide-loaded structure, the company explains that it can be utilized as a platform for various target protein degraders beyond tumors.

Naivek already possesses a 'cell-permeable synthetic peptide (CPP)' drug delivery system that targets only cancer cells. They added an scFv sequence capable of binding K-RAS and a proteasome-inducing sequence to this. Through this, the scFv that reaches cancer cells binds to mutant K-RAS and activates proteasome degradation.

According to the protein analysis method 'SPR (Surface Plasmon Resonance analysis)', the degrader not only showed high binding affinity to mutant K-RAS but also affected the proliferation of various types of K-RAS mutant cells in cell viability tests. In vivo studies further confirmed a significant reduction in tumor growth and degradation of K-RAS.

A Naivek representative stated, "Attempts to directly target mutant K-RAS have achieved some success in treating certain cancers, but resistance remains a challenge," adding, "The targeted protein degradation anticancer drug currently under development is an upgraded version of scFv developed in collaboration with existing pharmaceutical companies into a cell-permeable protein degrader, making it an optimal substance to overcome resistance issues seen in chemical drugs."

He continued, "Since scFv has limited cell permeability, we maximized efficacy by using cell-permeable synthetic peptide (CPP) as a drug delivery vehicle," emphasizing, "The new anticancer drug has high utility as a platform for developing various protein degraders in the future, attracting great interest from global big pharma."

This content was produced with the assistance of AI translation services.